- Poster presentation
- Open Access
MRI pelvis screening to guide treatment of pelvic pathology
© Bryant and LeBlang; licensee BioMed Central Ltd. 2015
Published: 30 June 2015
The purpose of this retrospective study is to examine the incidence and imaging appearance of pelvic malignancies in a symptomatic patient population being screened for MRgFUS treatment.
373 women with symptomatic uterine fibroids were screened with MRI exams with and without contrast utilizing T2 coronal and axial, T2 fat suppressed sagittal, T1 axial precontrast images, and post contrast fat saturated images in 3 planes. Uterine masses were classified by their intensity on T2 weighted images relative to normal myometrium (hypointense, isointense, or hyperintense as well as tissue homogeneity or heterogeneity). The enhancement pattern was also categorized as homogenous or inhomogeneous. Any extra-uterine masses were also noted as well as any other incidental pelvic findings.
Results and conclusions
Results: Of the 373 patients (ages 26-61) that underwent pelvic screening for MRgFUS treatment, 19 presented with findings suspicious for cancer and after further evaluation, 7 of these patients (1.9 %) were confirmed to have a pelvic malignancy. 5 patients had a uterine sarcoma, 1 had endometrial carcinoma and 1 had ovarian carcinoma. Three out of the five sarcomas appeared markedly heterogeneous on T2 weighted images with ill-defined dark areas and bright fluid components and demonstrated heterogeneous, poorly defined areas of enhancement throughout. The remaining 2 sarcomas appeared more fluid in nature with eccentric, enhancing soft tissue components and multiple septations.
Patients excluded from MRgFUS treatment due to the possibility of underlying malignancy.
Reason for Suspected Malignancy
Number of Patients
Heterogeneous enhancement with ill-defined areas of hypo-enhancement
Intra-cavitary mass w/blood products and heterogeneous enhancement
Intra-cavitary masswith homogenous enhancement
Heterogeneous enhancement with well-defined hypo-enhancement
We would like to thank Lisa Mckenzie and Gina Boykin for their knowledge and dedication in helping to take care of our MRgFUS patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.